Trade & Channel

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

A session investigates the drivers of these shortages and ways to mitigate them.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.

Companies striving for transformed and targeted growth are exploring strategies that include partnerships, artificial intelligence, increased efficiencies, and competitive intelligence.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.

New collaboration seeks to take a significant step in the development of targeted treatments for solid tumors and an expansion of opportunities in the growing antibody-drug conjugate market.

Rusfertide could potentially be a first-in-class, transformational treatment for polycythemia vera.

Sandoz will buy Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab), for an upfront cash payment of $170 million.

The US Department of Defense awarded Emergent BioSolutions Inc. with a contract worth up to $235.8 million to supply all branches of the US military with BioThrax (Anthrax Vaccine Adsorbed) for use as pre-exposure prophylaxis against anthrax disease.

Breakout session summarizes key areas that will affect all aspects of the industry.

Session discusses ways to integrate digital pharmacies and hubs.

Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.

Conference keynote offers an industry outlook, including new commercialization challenges.

Adults and children aged 1 year and older are eligible for the IV formulation of Cresemba for invasive aspergillosis and invasive mucormycotic, whereas the prescribed capsule is only indicated for adults and children 6 years of age and older.

An independent Data Monitoring Committee found that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit vs. Keytruda in combination with chemotherapy followed by Keytruda plus a placebo in patients with metastatic squamous non-small cell lung cancer.

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Session explores how on-market products have done, and what to expect from new biosimilars.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.

Phathom Pharmaceuticals announced that it anticipates vonoprazan (Voquenza) to be commercially available by December 2023.

SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.

The branded form of secukinumab is currently the only FDA-approved fully human biologic that directly inhibits interleukin-17A.

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.